{
    "root": "3593e687-4c04-7c1b-e063-6294a90aaba2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Capecitabine",
    "value": "20250520",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "CAPECITABINE",
            "code": "6804DJ8Z9U"
        }
    ],
    "indications": "capecitabine nucleoside metabolic inhibitor indicated : colorectal cancer adjuvant treatment patients stage iii colon cancer single agent component combination chemotherapy regimen . ( 1.1 ) perioperative treatment adults locally advanced rectal cancer component chemoradiotherapy . ( 1.1 ) treatment patients unresectable metastatic colorectal cancer single agent component combination chemotherapy regimen . ( 1.1 ) breast cancer treatment patients advanced metastatic breast cancer single agent anthracycline- taxane-containing chemotherapy indicated . ( 1.2 ) treatment patients advanced metastatic breast cancer combination docetaxel disease progression prior anthracycline-containing chemotherapy . ( 1.2 ) gastric , esophageal , gastroesophageal junction cancer treatment adults unresectable metastatic gastric , esophageal , gastroesophageal junction cancer component combination chemotherapy regimen . ( 1.3 ) treatment adults her2-overexpressing metastatic gastric gastroesophageal junction adenocarcinoma received prior treatment metastatic disease component combination regimen . ( 1.3 ) pancreatic cancer adjuvant treatment adults pancreatic adenocarcinoma component combination chemotherapy regimen . ( 1.4 )",
    "contraindications": "adjuvant treatment colon cancer single agent : 1,250 mg/m 2 twice daily orally first 14 days 21-day cycle maximum 8 cycles . ( 2.1 ) combination oxaliplatin-containing regimens : 1,000 mg/m 2 orally twice daily first 14 days 21-day cycle maximum 8 cycles combination oxaliplatin 130 mg/m 2 administered intravenously day 1 cycle . ( 2.1 ) perioperative treatment rectal cancer concomitant radiation therapy : 825 mg/m 2 orally twice daily ( 2.1 ) without radiation therapy : 1,250 mg/m 2 orally twice daily ( 2.1 ) unresectable metastatic colorectal cancer : single agent : 1,250 mg/m 2 twice daily orally first 14 days 21-day cycle disease progression unacceptable toxicity . ( 2.1 ) combination oxaliplatin : 1,000 mg/m 2 orally twice daily first 14 days 21-day cycle disease progression unacceptable toxicity combination oxaliplatin 130 mg/m 2 administered intravenously day 1 cycle . ( 2.1 ) advanced metastatic breast cancer : single agent : 1,000 mg/m 2 1,250 mg/m 2 twice daily orally first 14 days 21-day cycle disease progression unacceptable toxicity . ( 2.2 ) combination docetaxel : 1,000 mg/m 2 1,250 mg/m 2 orally twice daily first 14 days 21-day cycle , disease progression unacceptable toxicity combination docetaxel 75 mg/m 2 administered intravenously day 1 cycle ( 2.2 ) unresectable metastatic gastric , esophageal , gastroesophageal junction cancer 625 mg/m 2 orally twice daily days 1 21 21-day cycle maximum 8 cycles combination platinum-containing chemotherapy . ( 2.3 ) 850 mg/m 2 1,000 mg/m 2 orally twice daily first 14 days 21-day cycle disease progression unacceptable toxicity combination oxaliplatin 130 mg/m 2 administered intravenously day 1 cycle . ( 2.3 ) her2-overexpressing metastatic adenocarcinoma gastroesophageal junction stomach 1,000 mg/m 2 orally twice daily first 14 days 21-day cycle disease progression unacceptable toxicity combination cisplatin trastuzumab . ( 2.3 ) pancreatic cancer 830 mg/m 2 orally twice daily first 21 days 28-day cycle maximum 6 cycles combination gemcitabine 1,000 mg/m 2 administered intravenously days 1 , 8 , 15 cycle . ( 2.4 ) refer sections 2.5 2.6 information related modifications renal impairment ( 2.5 2.6 ) .",
    "warningsAndPrecautions": "capecitabine tablets , usp available follows : 150 mg : peach light peach , oblong , film-coated , biconvex , unscored tablets , debossed 190 one side 77 side . available bottles 60 tablets ( ndc 51407-639-60 ) . 500 mg : peach light peach , oblong , film-coated , biconvex , unscored tablets debossed 191 one side 77 side . available bottles 120 tablets ( ndc 51407-640-12 ) . storage handling store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp , child-resistant closure ( required ) . keep tightly closed . keep medications reach children . capecitabine hazardous . follow applicable special handling disposal procedures . 1",
    "adverseReactions": "capecitabine contraindicated patients history severe hypersensitivity reaction fluorouracil capecitabine [ ( 6.1 ) ] .",
    "indications_original": "Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 )",
    "contraindications_original": "Adjuvant Treatment of Colon Cancer Single agent: 1,250 mg/m 2 twice daily orally for the first 14 days of each 21-day cycle for a maximum of 8 cycles. ( 2.1 ) In combination with Oxaliplatin-Containing Regimens: 1,000 mg/m 2 orally twice daily for the first 14 days of each 21-day cycle for a maximum of 8 cycles in combination with oxaliplatin 130 mg/m 2 administered intravenously on day 1 of each cycle. ( 2.1 ) Perioperative Treatment of Rectal Cancer With Concomitant Radiation Therapy: 825 mg/m 2 orally twice daily ( 2.1 ) Without Radiation Therapy: 1,250 mg/m 2 orally twice daily ( 2.1 ) Unresectable or Metastatic Colorectal Cancer: Single agent: 1,250 mg/m 2 twice daily orally for the first 14 days of each 21-day cycle until disease progression or unacceptable toxicity. ( 2.1 ) In Combination with Oxaliplatin: 1,000 mg/m 2 orally twice daily for the first 14 days of each 21-day cycle until disease progression or unacceptable toxicity in combination with oxaliplatin 130 mg/m 2 administered intravenously on day 1 of each cycle. ( 2.1 ) Advanced or Metastatic Breast Cancer: Single agent: 1,000 mg/m 2 or 1,250 mg/m 2 twice daily orally for the first 14 days of each 21-day cycle until disease progression or unacceptable toxicity. ( 2.2 ) In combination with docetaxel: 1,000 mg/m 2 or 1,250 mg/m 2 orally twice daily for the first 14 days of a 21-day cycle, until disease progression or unacceptable toxicity in combination with docetaxel at 75 mg/m 2 administered intravenously on day 1 of each cycle ( 2.2 ) Unresectable or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Cancer 625 mg/m 2 orally twice daily on days 1 to 21 of each 21-day cycle for a maximum of 8 cycles in combination with platinum-containing chemotherapy. ( 2.3 ) OR 850 mg/m 2 or 1,000 mg/m 2 orally twice daily for the first 14 days of each 21-day cycle until disease progression or unacceptable toxicity in combination with oxaliplatin 130 mg/m 2 administered intravenously on day 1 of each cycle. ( 2.3 ) HER2-overexpressing metastatic adenocarcinoma of the gastroesophageal junction or stomach 1,000 mg/m 2 orally twice daily for the first 14 days of each 21-day cycle until disease progression or unacceptable toxicity in combination with cisplatin and trastuzumab. ( 2.3 ) Pancreatic cancer 830 mg/m 2 orally twice daily for the first 21 days of each 28-day cycle for maximum of 6 cycles in combination with gemcitabine 1,000 mg/m 2 administered intravenously on days 1, 8, and 15 of each cycle. ( 2.4 ) Refer to Sections 2.5 and 2.6 for information related to dosage modifications for adverse reactions and renal impairment ( 2.5 and 2.6 ).",
    "warningsAndPrecautions_original": "Capecitabine tablets, USP are available as follows:\n                  150 mg: Peach to light peach, oblong, film-coated, biconvex, unscored tablets, debossed with 190 on one side and 77 on the other side. Available in bottles of 60 tablets (NDC 51407-639-60).\n                  500 mg: Peach to light peach, oblong, film-coated, biconvex, unscored tablets debossed with 191 on one side and 77 on the other side. Available in bottles of 120 tablets (NDC 51407-640-12).\n                  \n                     Storage and Handling\n                  \n                  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  KEEP TIGHTLY CLOSED.\n                  Keep this and all medications out of the reach of children.\n                  Capecitabine is a hazardous drug. Follow applicable special handling and disposal procedures. \n  1",
    "adverseReactions_original": "Capecitabine is contraindicated in patients with history of severe hypersensitivity reaction to fluorouracil or capecitabine\n \n  [see Adverse Reactions (\n  \n   6.1)]\n \n  ."
}